<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404001</url>
  </required_header>
  <id_info>
    <org_study_id>MCP-104-201</org_study_id>
    <nct_id>NCT00404001</nct_id>
  </id_info>
  <brief_title>Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia</brief_title>
  <official_title>A Phase 2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Study of the Safety and Efficacy of Orally Administered MD-0727 in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironwood Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety of MD-0727 in patients with
      primary hypercholesterolemia and to determine the low density lipoprotein cholesterol (LDL-C)
      lowering effect and dose-response of MD-0727 in patients with primary hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL-C)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
  </secondary_outcome>
  <enrollment type="Actual">150</enrollment>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MD-0727</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or non-pregnant, non-breastfeeding female, at least 18 years of age

          -  Patient must agree to use contraception and/or birth control if sexually active

          -  Patient may not be on lipid-lowering therapies at least 6 weeks prior to study and
             must have a fasting LDL-C 130 mg/dl or greater at Screening

          -  Patient must have an average of two fasting LDL-C measures greater than/equal to 130
             mg/dl but less than/equal to 210 mg/dl with a difference in the two measures less
             than/equal to 15%. Patient may not have a fasting serum triglyceride less than 300
             mg/dl during Pre-treatment Period

          -  Patient's BMI must be greater than/equal to 18.5 but less than 35.0 at Screening

          -  Patient must complete a physical exam, 12-lead ECG, and other laboratory tests
             (including pregnancy test) with no clinically-significant findings prior to the first
             dose of study medication

          -  Patient agrees to comply with the TLC diet

          -  Patient completes a 6-week washout of previous lipid-lowering medication including
             over-the-counter products

        Exclusion Criteria:

          -  Patient has a medical condition that is prohibited per protocol or a condition that
             the Investigator believes may limit the patient's ability to participate in the study

          -  Patient has a TSH level &gt;1.5 X the upper limit of normal

          -  Patient has history of cardiovascular or coronary artery disease, uncontrolled
             endocrine or metabolic disease known to influence serum lipids or lipoproteins, or
             patient has history of NYHA Class III or IV congestive heart failure

          -  Patient is diabetic or presents with fasting blood glucose greater than/equal to 126
             mg/dl at any time prior to randomization

          -  Patient has uncontrolled hypertension with a systolic blood pressure greater
             than/equal to 180 mm Hg or diastolic blood pressure greater than/equal to 110 mmg Hg
             at two study visits prior to the first dose of study medication

          -  Patient has a 10-year CHD risk of &gt; 20%

          -  Patient has ALT or AST &gt; 1.5 X the upper limit of normal prior to randomization

          -  Patient has a history of alcohol or drug abuse within 12 months of Screening

          -  Patient has used a prohibited medication (per protocol) during the 14-day
             Pre-treatment Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Microbia Medical Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Microbia, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Overland</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Lakewood</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2006</study_first_submitted>
  <study_first_submitted_qc>November 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2006</study_first_posted>
  <last_update_submitted>September 28, 2007</last_update_submitted>
  <last_update_submitted_qc>September 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2007</last_update_posted>
  <keyword>Microbia</keyword>
  <keyword>MD-0727</keyword>
  <keyword>Primary Hypercholesterolemia</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>LDL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

